Mesa Labs Q2 revenue up 64% but GAAP EPS down 65%; non-GAAP AOI up 55%

MESA LABORATORIES INC /CO/

2024-Q2 EPS reported -$0.02 revenue$109,202,000

Revenue $58.7M (+64% YoY); organic growth 12% (18% constant currency). Net income $1.3M (-65%), diluted EPS $0.24.
GAAP operating income $4.0M (-5%); non-GAAP AOI $15.5M (+55%), $2.88 per diluted share.
Segments: Clinical Genomics $18.4M (+27% seq), Sterilization $17.0M (+21% org), Biopharma $12.1M (+15% org), Calibration $11.2M flat.
H1 revenue $109.2M (+54%); GAAP operating loss $0.6M, net loss $0.1M; non-GAAP AOI $21.6M (+13%).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MESA LABORATORIES INC /CO/ reported three and six months ended September 30, 2022 results: revenue $58,749, net income $1,306, EPS $0.24 per diluted share.

Period: three and six months ended September 30, 2022
Revenue: $58,749
Net income: $1,306
EPS: $0.24 per diluted share
Result: reported results

Exact text from the filing

In comparison to the same quarter in the prior year (“2Q22”), revenues increased 64% to $58,749, operating income decreased 5% to $3,995 and net income was $1,306, a decrease of 65% or $0.24 per diluted share of common stock.

View on SEC.gov

Browse all earnings releases →

MESA LABORATORIES INC /CO/ filing history →

Source: SEC EDGAR

accession 0001437749-22-025648

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.